Trending...
- Governor Gavin Newsom signs SB 27, strengthening California's CARE Act and expanding access to behavioral health services
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
- Richline Transportation Expands Luxury Airport Transfer and Black Car Service in San Diego
SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on September 15, 2020, the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to purchase an aggregate of 68,825 shares of its common stock and 12,420 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of September 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $69.25 per share, the closing price of Arena's common stock on the grant date, and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in substantially equal monthly installments over the following 36 months, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement RSUs vest over four years, with 25% of the shares vesting on the first quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarterly installments occurring on the following 12 quarterly vesting dates, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement stock options and inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2020 Long-Term Incentive Plan.
More on The Californer
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
More on The Californer
Corporate Contact:
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
[email protected]
858.210.3635
Arena Media Contact:
[email protected]
858.453.7200
SOURCE Arena Pharmaceuticals, Inc.
Related Links
http://www.arenapharm.com
The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $69.25 per share, the closing price of Arena's common stock on the grant date, and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in substantially equal monthly installments over the following 36 months, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement RSUs vest over four years, with 25% of the shares vesting on the first quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarterly installments occurring on the following 12 quarterly vesting dates, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement stock options and inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2020 Long-Term Incentive Plan.
More on The Californer
- City of Long Beach Introduces Interest Form to Connect Local Businesses and Property Owners with 2028 Games Stakeholders
- Six-Figure Chicks Book Series 96 Authors, 6 Volumes Published to Empower and Mentor Women Nationwide
- MTN WTR Partners with Sumo + Sushi 2025 U.S. Tour to Celebrate Japanese Culture Across Five Cities
- Hundreds of new homes for veterans are coming to California through voter-approved Prop 1 funding
- LSC Destruction Launches Cutting-Edge Cryptocurrency Scanning to Hard Drive Destruction Services
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
More on The Californer
- California highlights earthquake preparedness for Great ShakeOut Day
- DALPS Announces Global Airdrop to Reward Users and Expand Its Offers Marketplace
- Governor Newsom expands response arsenal with new emergency services facility in Southern California
- ALYXX Features on Oceans In Silhouette "Under My Skin" Single
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
Corporate Contact:
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
[email protected]
858.210.3635
Arena Media Contact:
[email protected]
858.453.7200
SOURCE Arena Pharmaceuticals, Inc.
Related Links
http://www.arenapharm.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom calls for congressional investigation into vile, antisemitic and violent messages from MAGA organization
- Premier Workspaces Elevates Its San Francisco Presence at One Sansome Street
- Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- City of Long Beach Launches Local Hiring Preferences
- The Mogharebi Group Facilitates $34.6 Million Sale of Willow Grove Apartments in Modesto, CA
- UK Website Launches "Toy Time Machine" — Find Your Childhood Christmas Toy in One Click
- Rachel Farris, CPA Named Among Forbes' Top CPAs in America
- California: Crime is down in San Francisco, key law enforcement partnerships yield successful results
- Scott St. Germain, U.S. Army Veteran and Vice President at Genentech, Joins Dream Foundation Board
- New West Symphony: E.T. The Extra-Terrestrial in Concert
- Vesper Public Relations is selected as an official supplier of the LASEC Business Connect Program
- California announces coalition of Governors forming new alliance to protect public health from political interference
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- Thread Advisory Group Launches to Help Retailers Turn Strategy Into Lasting Results
- QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI
- New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
- Inside the Practice of a Caring Dentist Bringing Personalized Care to La Jolla
- Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
- City of Long Beach Confirms First Case of Clade I Mpox